Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma

American Journal of Surgical Pathology

Volumn 33, Issue 8, 2009, Pages 1146-1156

  Gerami, Pedram ^a   Jewell, Susan S ^b   Morrison, Larry E ^b   Blondin, Beth ^b   Schulz, John ^b   Ruffalo, Teresa ^b   Matushek IV, Paul ^b   Legator, Mona ^b   Jacobson, Kristine ^b   Dalton, Scott R ^d   Charzan, Susan ^c   Kolaitis, Nicholas A ^c   Guitart, Joan ^a   Lertsbarapa, Terakeith ^a   Boone, Susan ^a   LeBoit, Philip E ^c   Bastian, Boris C ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Abbott Molecular Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

FISH; Melanoma; Spitz nevi; Spitz tumor

Indexed keywords

ALGORITHM; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CENTROMERE; CHROMOSOME 11Q; CHROMOSOME 6P; CHROMOSOME 6Q; CHROMOSOME MUTATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; ALGORITHMS; CHILD; FEMALE; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MELANOMA; NEVUS, EPITHELIOID AND SPINDLE CELL; ROC CURVE; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 67650283437     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181a1ef36     Document Type: Article

References (37)

1. ACS. melanoma. In: 2007. http://www.cancer.org/docroot/CRI/ CRI-2x.asp?sitearea=LRN&dt=39.
2. Balaban G, Herlyn M, Guerry D, et al. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet. 1984;11:429-439.
3. Barnhill RL, Piepkorn M, Busam KJ. Pathology of Melanocytic Nevi and Malignant Melanoma. New York: Springer-Verlag; 2004.
4. Bastian BC, Leboit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58:2170-2175.
5. Bastian BC, Wesselmann U, Pinkel D, et al. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol. 1999;113:1065-1069.
6. Bastian BC, Olshen AB, Leboit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003; 163:1765-1770.
7. Burton RC, Armstrong BK. Current melanoma epidemic: a nonmetastasizing form of melanoma? World J Surg. 1995;19:330-333.
8. Cochran AJ, Bailly C, Cook M, et al. Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. The association of directors of anatomic and surgical pathology. Am J Clin Pathol. 1998;110:719-722.
9. Corona R, Mele A, Amini M, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol. 1996;14:1218-1223.
10. Cowan JM, Halaban R, Francke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst. 1988;80:1159-1164.
11. Crowson N, Magro C, Mihm MC. The Melanocytic Proliferations. New York: Wiley-Liss, Inc; 2001.
12. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-2147.
13. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340-4346.
14. Del MC, Green A, Cooney T, et al. Melanocytic lesions excised from the skin: what percentage are malignant? Aust J Public Health. 1994;18:221-223.
15. English DR, Del MC, Burton RC. Factors influencing the number needed to excise: excision rates of pigmented lesions by general practitioners. Med J Aust. 2004;180:16-19.
16. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 1996;27:528-531.
17. Gerami P, Guitart J, Martini M, et al. Cyclin D1 homogeneous staining regions by fluorescent in situ hybridization: a possible indicator of aggressive behaviour. Arch Dermatol. 2008;144:1235-1236.
18. Heselmeyer-Haddad K, Sommerfeld K, White NM, et al. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol. 2005; 166:1229-1238.
19. Jackson R. Malignant melanoma: a review of 75 malpractice cases. Int J Dermatol. 1997;36:497-498.
20. Kempf W, Haeffner AC, Mueller B, et al. Experts and gold standards in dermatopathology: qualitative and quantitative analysis of the self-assessment slide seminar at the 17th colloquium of the International Society of Dermatopathology. Am J Dermatopathol. 1998;20:478-482.
21. Lee JY, Dong SM, Shin MS, et al. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun. 1997;237:667-672.
22. Limon J, Dal CP, Sait SN, et al. Chromosome changes in metastatic human melanoma. Cancer Genet Cytogenet. 1988;30:201-211.
23. Lodha S, Saggar S, Celebi JT, et al. Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting. J Cutan Pathol. 2008;35:349-352.
24. Massi G, Leboit PE. Histological Diagnosis of Nevi and Melanoma. Berlin: Springer Verlag; 2004.
25. McGinnis KS, Lessing SR, Elder DE, et al. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol. 2002;138:617-621.
26. Mertens F, Johansson B, Mitelman F. Isochromosomes in neoplasia. Genes Chromosomes Cancer. 1994;10:221-230.
27. Mooi WJ, Krausz T. Pathology of Melancytic Disorders. New York, NY: Oxford University Press; 2007. Incorporated.
28. Park WS, Vortmeyer AO, Pack S, et al. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum Pathol. 1998;29:127-130.
29. Parmiter AH, Nowell PC. The cytogenetics of human malignant melanoma and premalignant lesions. Cancer Treat Res. 1988;43:47-61.
30. Piepkorn MW, Barnhill RL, Cannon-Albright LA, et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol. 1994;30:707-714.
31. Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. 2000;2:116-123.
32. Sokolova IA, Bubendorf L, O'Hare A, et al. A fluorescence in situ hybridization-based assay for improved detection of lung cancer cells in bronchial washing specimens. Cancer. 2002;96:306-315.
33. Thomas JM. The place of sentinel node biopsy in melanoma after the Multicenter Selective Lymphadenectomy Trial. ANZ J Surg. 2006;76:98-99.
34. Troxel DB, Sabella JD. Problem areas in pathology practice. Uncovered by a review of malpractice claims. Am J Surg Pathol. 1994;18:821-831.
35. Veenhuizen KC, De Wit PE, Mooi WJ, et al. Quality assessment by expert opinion in melanoma pathology: experience of the pathology panel of the Dutch Melanoma Working Party. J Pathol. 1997;182: 266-272.
36. Wakely SL, Baxendine-Jones JA, Gallagher PJ, et al. Aberrant diagnoses by individual surgical pathologists. Am J Surg Pathol. 1998;22:77-82.
37. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331:481.